Merlin inhibits Wnt/β-catenin signaling by blocking LRP6 phosphorylation

Area of Science:

• Molecular Biology
• Cell Signaling
• Oncology

Background:

• Merlin, encoded by the NF2 gene, is a tumor suppressor involved in regulating cell signaling.
• Mutations in Merlin cause Neurofibromatosis type II (NF2), a disease where its precise molecular mechanism remains unclear.
• Wnt/β-catenin signaling is crucial for development and implicated in various cancers.

Purpose of the Study:

• To elucidate the molecular mechanism by which Merlin suppresses tumor growth.
• To investigate Merlin's role in regulating Wnt/β-catenin signaling.
• To determine the link between Merlin dysfunction, Wnt/β-catenin signaling, and NF2 pathogenesis.

Main Methods:

• Investigated Merlin's interaction with Wnt pathway components using cell-based assays.
• Analyzed Merlin phosphorylation status and its effect on LRP6 phosphorylation.
• Examined β-catenin levels in NF2 patient tissues and assessed the impact of Wnt/β-catenin inhibitors on cancer cell proliferation.

Main Results:

• Merlin inhibited Wnt/β-catenin signaling by blocking LRP6 phosphorylation; mutated Merlin lost this function.
• Wnt3a treatment induced Merlin phosphorylation via PAK1, leading to Merlin dissociation from LRP6 and subsequent LRP6 phosphorylation.
• NF2 patient tissues showed elevated β-catenin, and Wnt/β-catenin pathway inhibition reduced schwannoma cell proliferation.

Conclusions:

• Merlin's tumor-suppressive function involves inhibiting Wnt/β-catenin signaling through LRP6 phosphorylation.
• Dysfunctional Merlin in NF2 leads to sustained Wnt/β-catenin activation.
• Aberrant Wnt/β-catenin signaling due to Merlin loss-of-function is a potential driver of NF2 disease.